Friday, 9 June 2017

Global HER-2 Positive Breast Cancer Market 2017 Industry Size, Research, Trends, Review & Analysis to 2019


About HER-2 Positive Breast Cancer Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9
percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

TechNavio's analysts forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019.

                                
Covered in this Report This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global HER-2 Positive Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global HER-2 Positive Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global HER-2 Positive Breast Cancer market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions • Americas
• APAC
• EMEA

Key Vendors • Celgene
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novartis
• Sanofi

Other Prominent Vendors • Actavis
• Array BioPharma
• Biocad
• Biocon
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celltrion
• Chugai Pharmaceutical
• DARA BioSciences
• EddingPharm
• Eisai
• Galena Biopharma
• Halozyme Therapeutics
• Hospira
• Mylan
• Oncothyreon
• Pfizer
• ProStrakan
• Puma Biotechnology
• Sun Pharmaceutical Industries
• Synta Pharmaceuticals
• Teva Pharmaceutical

Market Driver • Increase in Population of Breast Cancer Patients
• For a full, detailed list, view our report

Market Challenge • Poor Diagnosis and Screening
• For a full, detailed list, view our report

Market Trend • Increase in Awareness 
• For a full, detailed list, view our report

Key Questions Answered in this Report • What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

                                                                                                                                      
Table of Contents         
  1. Executive Summary
    02. List of Abbreviations
    03. Scope of the Report
        03.1 Market Overview
        03.2 Product Offerings
    04. Market Research Methodology
        04.1 Market Research Process
        04.2 Research Methodology
    05. Introduction
    06. Disease Overview
        06.1 Understanding the Disease
        06.2 Pathophysiology
        06.3 Epidemiology
        06.4 Diagnosis
          06.4.1 Immunohistochemistry
          06.4.2 FISH
          06.4.3 SPoT-Light HER2 CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization)
          06.4.4 Inform HER2 Dual ISH Test (Inform Dual In Situ Hybridization)
        06.5 Management
          06.5.1 Surgery
          06.5.2 Radiotherapy
          06.5.3 Chemotherapy
          06.5.4 Targeted Therapy
          06.5.5 Hormonal Therapy
        06.6 Economic Burden
    07. Pipeline Analysis
    08. Market Landscape
        08.1 Market Overview
        08.2 Market Size and Forecast
        08.3 HER-2 Positive Breast Cancer Market in US
          08.3.1 Market Size and Forecast
        08.4 HER-2 Positive Breast Cancer Market in EU
          08.4.1 Market Size and Forecast
        08.5 Five Forces Analysis
    09. Market Segmentation by Type of Therapy
        09.1 Chemotherapy
          09.1.1 Alkylating agents
          09.1.2 Antimetabolites
          09.1.3 Cytotoxic antibiotics
          09.1.4 Taxanes
        09.2 Targeted Therapy
        09.3 Hormone Therapy
    10. Market Segmentation by Molecule Type
        10.1 Biologics
        10.2 Small Molecules
    11. Market Segmentation by Route of Administration
        11.1 Oral
        11.2 Parenteral
    12. Geographical Segmentation
    13. Buying Criteria
    14. Market Growth Drivers
    15. Drivers and their Impact
    16. Market Challenges
    17. Impact of Drivers and Challenges
    18. Market Trends
    19. Trends and their Impact
    20. Vendor Landscape
        20.1 Competitive Scenario
          20.1.1 Key News
          20.1.2 Mergers and Acquisitions
        20.2 Market Share Analysis 2014
          20.2.1 Competitive Assessment of the Top Drugs
          20.2.2 Celgene
          20.2.3 F. Hoffmann-La Roche
          20.2.4 GlaxoSmithKline
          20.2.5 Novartis
          20.2.6 Sanofi
        20.3 SWOT Analysis of the Targeted Therapies
          20.3.1 Herceptin
          20.3.2 Kadcyla
          20.3.3 Perjeta
          20.3.4 Tykerb
        20.4 Other Prominent Vendors
    21. Key Vendor Analysis
        21.1 Celgene     21.1.1 Key Facts
          21.1.2 Business Overview
          21.1.3 Business Strategy
          21.1.4 Business Segmentation by Revenue
          21.1.5 Sales by Geography
          21.1.6 Key Information
          21.1.7 SWOT Analysis
    21.2 F. Hoffmann-La Roche       21.2.1 Key Facts
          21.2.2 Business Overview
          21.2.3 Business Segmentation
          21.2.4 Business Segmentation by Revenue 2012 and 2013
          21.2.5 Sales by Geography
          21.2.6 Business Strategy
          21.2.7 Key Information
          21.2.8 SWOT Analysis
        21.3 GlaxoSmithKline       21.3.1 Key Facts
          21.3.2 Business Overview
          21.3.3 Business Segmentation
          21.3.4 Business Segmentation by Revenue 2012 and 2013
          21.3.5 Sales by Geography
          21.3.6 Pipeline Products
          21.3.7 Business Strategy
          21.3.8 Key Information
          21.3.9 SWOT Analysis
        21.4 Novartis       21.4.1 Key Facts
          21.4.2 Business Description
          21.4.3 Business Segmentation
          21.4.4 Revenue by Business Segmentation
          21.4.5 Revenue Comparison 2012 and 2013
          21.4.6 Sales by Geography
          21.4.7 Business Strategy
          21.4.8 Key Developments
          21.4.9 SWOT Analysis
        21.5 Sanofi       21.5.1 Key Facts
          21.5.2 Business Description
          21.5.3 Business Segmentation
          21.5.4 Revenue by Business Segmentation
          21.5.5 Revenue Comparison 2012 and 2013
          21.5.6 Sales by Geography
          21.5.7 Business Strategy
          21.5.8 Key Developments
          21.5.9 SWOT Analysis
    22. Other Reports in this Series
Continued…….

                                                                                                                                                                      
CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)